Clindamycin Phosphate
56 NDCs across 16 manufacturers|45 Generic,11 Brand
Clindamycin Phosphate is used to treat acne vulgaris, actinomycetales infections, bacteroides infections, pneumocystis pneumonia, staphylococcal infections and streptococcal infections, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved before 1982, and the first generic was approved Jan 1, 1982. FDA's Orange Book lists 20 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $26 million on Clindamycin Phosphate across 679,000 claims for 347,000 beneficiaries.
Clindamycin Phosphate is available as 56 NDCs from 16 manufacturers (45 generic, 11 brand), with NADAC prices from $0.13 to $26.62 per GM — the most expensive product costs about 204× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Active FDA drug shortage
17 Clindamycin Phosphate presentations are currently listed in FDA's drug shortage database (first posted Mar 21, 2023). Shortages can move NADAC prices in the following weeks.
Total NDCs
56
45G / 11B
Manufacturers
16
competing in market
Price Spread
$0.13 – $26.62
per GM, 30 of 56 NDCs
7d Activity
avg -1.4% WoW · of 56 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Padagis Israel Pharmaceuticals Ltd manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Lincosamide Antibacterial class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
16 manufacturers producing CLINDAMYCIN PHOSPHATE(2 pricing outliers)
Frequently Asked Questions
What is Clindamycin Phosphate used to treat?
Clindamycin Phosphate is used to treat acne vulgaris, actinomycetales infections, bacteroides infections, pneumocystis pneumonia, staphylococcal infections and streptococcal infections, per the National Library of Medicine's MED-RT classification.
When did Clindamycin Phosphate become available as a generic?
FDA approved the first generic Clindamycin Phosphate (ANDA) on Jan 1, 1982. The Orange Book currently lists 20 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Clindamycin Phosphate?
In 2024, Medicare Part D spent $26 million on Clindamycin Phosphate across 679,000 claims for 347,000 beneficiaries.
Is Clindamycin Phosphate in shortage?
Yes — FDA's drug shortage database currently lists 17 Clindamycin Phosphate presentations with status "Current", first posted Mar 21, 2023.
How many Clindamycin Phosphate products are on the market?
The Clindamycin Phosphate drug market contains 56 NDCs from 16 manufacturers — 45 generic and 11 brand products.
What is the price range for Clindamycin Phosphate?
NADAC reference prices for Clindamycin Phosphate range from $0.1307 to $26.6211 per GM — the most expensive product costs about 204× the cheapest. 26 additional products are priced per different units (e.g. liquids per ML) and aren't directly comparable.
Is generic Clindamycin Phosphate cheaper than brand?
The average generic NADAC for Clindamycin Phosphate is $0.7454 per GM, versus $15.7607 for brand-labeled products — brand versions average about 21× the generic price.
Which manufacturers make Clindamycin Phosphate?
16 manufacturers list Clindamycin Phosphate in NADAC. Ranked by number of NDCs, the largest are Padagis Israel Pharmaceuticals Ltd (9), Pharmacia & Upjohn Company LLC (7), E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. (6), Glenmark Pharmaceuticals Inc., USA (4), Taro Pharmaceuticals U.S.A. Inc. (4).
How has the price of Clindamycin Phosphate changed recently?
Over the past 7 days, 18 Clindamycin Phosphate NDCs rose and 29 fell, with a market-wide average change of -1.4%.